New targeted drug versus standard chemotherapy for advanced breast cancer in crisis

Plain-English translation of NCT07203729 on ClinicalTrials.gov ↗ · Source last updated October 2026 · Translation generated August 2026 · How we translate trials

Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.

What is this trial?

This trial is testing a new drug called to see if it can help people with advanced breast cancer that is spreading rapidly and damaging vital organs like the liver or lungs. You would receive this medication every three weeks, or you might receive standard chemotherapy chosen by your doctor instead. Researchers want to learn whether this new treatment is safe and works better than traditional chemotherapy for this serious situation.

Some patients with advanced breast cancer experience rapid, life-threatening organ damage from their cancer — a condition called visceral crisis. Currently, standard chemotherapy is used, but doctors need better options that work faster and cause fewer side effects for these very sick patients.

Do you qualify?

You likely qualify if…

you are between 18 and 75 years old
you have been diagnosed with HER2-low breast cancer that has spread and cannot be surgically removed
your cancer is causing rapid, serious organ damage (such as liver or lung problems) that needs urgent treatment
you have received no more than one line of chemotherapy for your advanced cancer
you have adequate blood cell counts and bone marrow function as checked by blood tests
you are willing to use effective birth control if you could become pregnant, for the duration of treatment plus one year

You likely don't qualify if…

you have previously received any antibody-drug conjugate (ADC) therapy for breast cancer at any stage
your doctor believes you are not well enough for chemotherapy treatment
you have had another type of cancer within the past five years (except certain skin or cervical cancers)
you have severe heart disease, heart failure, or significant heart rhythm problems
you have had major surgery or serious injury within the past four weeks

What participation looks like

If you join this trial, you will be randomly assigned to receive either the new medication or standard chemotherapy. You will receive your treatment every three weeks as an injection or infusion, and you will continue until your cancer progresses or the side effects become too difficult to manage. You will have regular clinic visits and blood tests to monitor how well the treatment is working and to check for any side effects.

AI-generated summary from trial data · Aug 14, 2026 · Not medical advice

Trial locations(1 site)

China

Cancer Hospital, Chinese Academy of Medical Sciences, Beijing, Beijing Municipality